Found: 147
Select item for more details and to access through your institution.
How do we manufacture clinical-grade interleukin-15-stimulated natural killer cell products for cancer treatment?
- Published in:
- 2018
- By:
- Publication type:
- journal article
Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Molecular profiling refines minimal residual disease‐based prognostic assessment in adults with Philadelphia chromosome‐negative B‐cell precursor acute lymphoblastic leukemia.
- Published in:
- Genes, Chromosomes & Cancer, 2019, v. 58, n. 11, p. 815, doi. 10.1002/gcc.22788
- By:
- Publication type:
- Article
Copy number profiling of adult relapsed B-cell precursor acute lymphoblastic leukemia reveals potential leukemia progression mechanisms.
- Published in:
- Genes, Chromosomes & Cancer, 2017, v. 56, n. 11, p. 810, doi. 10.1002/gcc.22486
- By:
- Publication type:
- Article
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 1, p. E15, doi. 10.1002/ajh.26602
- By:
- Publication type:
- Article
Expression of p53 protein isoforms predicts survival in patients with multiple myeloma.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 6, p. 700, doi. 10.1002/ajh.26507
- By:
- Publication type:
- Article
Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 8, p. 853, doi. 10.1002/ajh.25507
- By:
- Publication type:
- Article
Early mortality in multiple myeloma: the time-dependent impact of comorbidity: A population-based study in 621 real-life patients.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 7, p. 700, doi. 10.1002/ajh.24389
- By:
- Publication type:
- Article
Do chronic myeloid leukemia patients with late 'warning' responses benefit from 'watch and wait' or switching therapy to a second generation tyrosine kinase inhibitor?
- Published in:
- American Journal of Hematology, 2014, v. 89, n. 11, p. E206, doi. 10.1002/ajh.23816
- By:
- Publication type:
- Article
Clinical significance of Gata-1, Gata-2, EKLF, and c-MPL expression in acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2009, v. 84, n. 2, p. 79, doi. 10.1002/ajh.21332
- By:
- Publication type:
- Article
Radiomics analysis of bone marrow biopsy locations in [<sup>18</sup>F]FDG PET/CT images for measurable residual disease assessment in multiple myeloma.
- Published in:
- Physical & Engineering Sciences in Medicine, 2023, v. 46, n. 2, p. 903, doi. 10.1007/s13246-023-01265-0
- By:
- Publication type:
- Article
Overcoming tumor resistance mechanisms in CAR-NK cell therapy.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 01, doi. 10.3389/fimmu.2022.953849
- By:
- Publication type:
- Article
Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis.
- Published in:
- European Journal of Haematology, 2017, v. 98, n. 4, p. 407, doi. 10.1111/ejh.12846
- By:
- Publication type:
- Article
Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP).
- Published in:
- Oncology & Therapy, 2023, v. 11, n. 1, p. 83, doi. 10.1007/s40487-022-00212-5
- By:
- Publication type:
- Article
Detection of minimal residual disease in acute myeloid leukemia: evaluating utility and challenges.
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1252258
- By:
- Publication type:
- Article
Usability Evaluation of a Noninvasive Neutropenia Screening Device (PointCheck) for Patients Undergoing Cancer Chemotherapy: Mixed Methods Observational Study.
- Published in:
- 2022
- By:
- Publication type:
- journal article
β-Thalassaemia Major in a Spanish Patient due to a Compound Heterozygosity for CD39 C → T/-28 A → C.
- Published in:
- 2009
- By:
- Publication type:
- Case Study
Mechanosensitive Ion Channels: Their Physiological Importance and Potential Key Role in Cancer.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 18, p. 13710, doi. 10.3390/ijms241813710
- By:
- Publication type:
- Article
Minimal Residual Disease Monitoring with Next-Generation Sequencing Methodologies in Hematological Malignancies.
- Published in:
- International Journal of Molecular Sciences, 2019, v. 20, n. 11, p. 2832, doi. 10.3390/ijms20112832
- By:
- Publication type:
- Article
Fatal graft-versus-host disease after allogeneic stem cell transplantation in a patient recently exposed to nivolumab.
- Published in:
- Journal of Oncology Pharmacy Practice, 2019, v. 25, n. 2, p. 502, doi. 10.1177/1078155217743069
- By:
- Publication type:
- Article
Multidisciplinary management in chronic myeloid leukemia improves cardiovascular risk measured by SCORE.
- Published in:
- Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1206893
- By:
- Publication type:
- Article
Long-Term Human Hematopoietic Stem Cell Culture in Microdroplets.
- Published in:
- Micromachines, 2021, v. 12, n. 1, p. 90, doi. 10.3390/mi12010090
- By:
- Publication type:
- Article
Droplet Microfluidics for the ex Vivo Expansion of Human Primary Multiple Myeloma Cells.
- Published in:
- Micromachines, 2020, v. 11, n. 3, p. 261, doi. 10.3390/mi11030261
- By:
- Publication type:
- Article
TYK2 Variants in B-Acute Lymphoblastic Leukaemia.
- Published in:
- Genes, 2020, v. 11, n. 12, p. 1434, doi. 10.3390/genes11121434
- By:
- Publication type:
- Article
Corrigendum.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. 545, doi. 10.1016/j.clml.2022.03.011
- By:
- Publication type:
- Article
P-226: Clinical outcomes of Multiple Myeloma patients after anti-CD38 monoclonal antibodies failure.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S164, doi. 10.1016/S2152-2650(21)02353-3
- By:
- Publication type:
- Article
P-148: Real-life analysis of the multiple myeloma patient's survival in a third-level hospital.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S116, doi. 10.1016/S2152-2650(21)02275-8
- By:
- Publication type:
- Article
P-137: ITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with Lenalidomide and Dexamethasone in high-risk smoldering Multiple Myeloma: safety run-in preliminary results.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S109, doi. 10.1016/S2152-2650(21)02264-3
- By:
- Publication type:
- Article
P-007: Exploring a safety switch in NKG2D and BCMA CAR NK-92MI immunotherapy.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S42, doi. 10.1016/S2152-2650(21)02141-8
- By:
- Publication type:
- Article
P-003: Improving NK cell function in Multiple Myeloma with NKTR-255, a novel polymer-conjugated human IL-15.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S40, doi. 10.1016/S2152-2650(21)02137-6
- By:
- Publication type:
- Article
OAB-056: A machine learning model based on tumor and immune biomarkers to predict undetectable measurable residual disease (MRD) in transplant-eligible multiple myeloma (MM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S35, doi. 10.1016/S2152-2650(21)02128-5
- By:
- Publication type:
- Article
OAB-035: Minimally invasive profiling of tumor and immune cells to stratify risk in smoldering multiple myeloma (SMM): the iMMunocell study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S22, doi. 10.1016/S2152-2650(21)02109-1
- By:
- Publication type:
- Article
OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S3, doi. 10.1016/S2152-2650(21)02079-6
- By:
- Publication type:
- Article
IBCL-195: Primary Analysis of the Phase 2 ELARA Trial: Tisagenlecleucel Efficacy and Safety in Adult Patients with Relapsed/Refractory Follicular Lymphoma (r/r FL).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S403, doi. 10.1016/S2152-2650(21)01911-X
- By:
- Publication type:
- Article
Poster: IBCL-195: Primary Analysis of the Phase 2 ELARA Trial: Tisagenlecleucel Efficacy and Safety in Adult Patients with Relapsed/Refractory Follicular Lymphoma (r/r FL).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S245, doi. 10.1016/S2152-2650(21)01539-1
- By:
- Publication type:
- Article
Phase 2 Clinical Trial of Infusing Haploidentical K562-mb15-41BBL–Activated and Expanded Natural Killer Cells as Consolidation Therapy for Pediatric Acute Myeloblastic Leukemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, n. 5, p. 328, doi. 10.1016/j.clml.2021.01.013
- By:
- Publication type:
- Article
Circulating Tumor Cells (CTCs) for Comprehensive and Multiregional Non-Invasive Genetic Characterization of Multiple Myeloma (MM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e351, doi. 10.1016/j.clml.2019.09.580
- By:
- Publication type:
- Article
Prolonged Lenalidomide Maintenace Therapy Improves the Quality and Deep of Response in Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e285, doi. 10.1016/j.clml.2019.09.470
- By:
- Publication type:
- Article
Clinical relevance of Minimal residual Disease assessment by NGS in Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e179, doi. 10.1016/j.clml.2019.09.300
- By:
- Publication type:
- Article
Detailed Phenotypic, Molecular and Functional Profiling of Myeloid Derived Suppressor Cells (MDSCs) in the Tumor Immune Micro-Environment (TIME) of Multiple Myeloma (MM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e97, doi. 10.1016/j.clml.2019.09.159
- By:
- Publication type:
- Article
Prognostic implications of MRD assessment in multiple myeloma patients: comparison of Next-Generation Sequencing and Next-Generation Flow.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e47, doi. 10.1016/j.clml.2019.09.071
- By:
- Publication type:
- Article
Exploring NKG2D and BCMA-CAR NK-92 for Adoptive Cellular Therapy to Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e24, doi. 10.1016/j.clml.2019.09.036
- By:
- Publication type:
- Article
ANCHOR (OP-104) Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI): Phase 1 Update.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S326, doi. 10.1016/j.clml.2019.07.313
- By:
- Publication type:
- Article
Quantification of proteins from CD138-purified myeloma cells using the capillary nano-immunoassay technology is a better predictor of survival than the corresponding gene expression value.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e4, doi. 10.1016/j.clml.2017.03.008
- By:
- Publication type:
- Article
The Presence of MDS-like Phenotypic Abnormalities (MDS-PA) Identifies Newly Diagnosed Multiple Myeloma (MM) Patients With MDS/AML-Related Somatic Mutations And Inferior Survival.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e11, doi. 10.1016/j.clml.2017.03.018
- By:
- Publication type:
- Article
Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.
- Published in:
- Advances in Therapy, 2024, v. 41, n. 4, p. 1576, doi. 10.1007/s12325-024-02797-x
- By:
- Publication type:
- Article
Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.
- Published in:
- Advances in Therapy, 2024, v. 41, n. 2, p. 696, doi. 10.1007/s12325-023-02738-0
- By:
- Publication type:
- Article
Biomarker-driven phase Ib clinical trial of OPB-111077 in acute myeloid leukemia.
- Published in:
- Medicine International (2754-3242), 2022, v. 2, n. 2, p. 1, doi. 10.3892/mi.2022.32
- By:
- Publication type:
- Article
Uncovering the Role of RNA-Binding Protein hnRNP K in B-Cell Lymphomas.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00805-x
- By:
- Publication type:
- Article